These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 12043424)

  • 61. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study].
    Ibsen H; Lindholm LH; Pedersen OL; Dahlöf B; Kjeldsen S
    Ugeskr Laeger; 2003 Jan; 165(5):459-62. PubMed ID: 12599844
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Views on marketing of a neuroleptic agent].
    Bendz H
    Lakartidningen; 1999 Nov; 96(47):5191-2. PubMed ID: 10608107
    [No Abstract]   [Full Text] [Related]  

  • 63. Long-term plasma catecholamines in patients with hypertension and left ventricular hypertrophy treated with losartan or atenolol: ICARUS, a LIFE substudy.
    Fossum E; Olsen MH; Høieggen A; Wachtell K; Reims HM; Ibsen H; Julius S; Kjeldsen SE
    J Hum Hypertens; 2004 Jun; 18(6):375-80. PubMed ID: 15057253
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Advertising gone too far?
    Quinn C
    Mark Health Serv; 2008; 28(4):20-3. PubMed ID: 19157035
    [No Abstract]   [Full Text] [Related]  

  • 65. [Blood pressure increases risk for dementia and stroke. Antihypertensive drugs for mental degeneration?].
    MMW Fortschr Med; 2004 Apr; 146(18):55. PubMed ID: 15366474
    [No Abstract]   [Full Text] [Related]  

  • 66. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study].
    Ibsen H; Pedersen OL; Dahlöf B; Kjeldsen SE; Lindholm LH
    Ugeskr Laeger; 2003 Jan; 165(5):456-9. PubMed ID: 12599843
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Adverse events in randomized trials: neglected, restricted, distorted, and silenced.
    Ioannidis JP
    Arch Intern Med; 2009 Oct; 169(19):1737-9. PubMed ID: 19858427
    [No Abstract]   [Full Text] [Related]  

  • 68. [Hypertension trials--for whom?].
    Hjelmqvist B
    Lakartidningen; 2005 Nov 21-27; 102(47):3587; discussion 3588-9. PubMed ID: 16408397
    [No Abstract]   [Full Text] [Related]  

  • 69. The role of the Federal Trade Commission in advertising health products and services.
    Daynard M
    J Am Coll Dent; 2004; 71(2):24-6. PubMed ID: 15347100
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study.
    Olsen MH; Wachtell K; Dahlöf B; Devereux RB; Ibsen H; Kjeldsen SE; Lindholm LH; Lyle PA; Nieminen MS
    J Hum Hypertens; 2006 Jun; 20(6):460-4. PubMed ID: 16572193
    [No Abstract]   [Full Text] [Related]  

  • 71. Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen.
    Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B;
    Heart; 2008 Feb; 94(2):e4. PubMed ID: 17916665
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Conflicts of interest between physicians and the pharmaceutical industry and special interest groups.
    Schetky DH
    Child Adolesc Psychiatr Clin N Am; 2008 Jan; 17(1):113-25, ix-x. PubMed ID: 18036482
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Dahlöf B; Burke TA; Krobot K; Carides GW; Edelman JM; Devereux RB; Diener HC
    J Hum Hypertens; 2004 Jun; 18(6):367-73. PubMed ID: 15029217
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Marketing drugs: debating the real cost. Concern about close ties between doctors and pharmaceutical firms are prompting new financial disclosure laws and education efforts.
    Brand R
    State Legis; 2008 Sep; 34(8):26-9. PubMed ID: 18754159
    [No Abstract]   [Full Text] [Related]  

  • 75. [Therapy of hypertension in patients with atrial fibrillation. Sartan is superior to beta-blocker].
    MMW Fortschr Med; 2003 May; 145(19):53. PubMed ID: 12813983
    [No Abstract]   [Full Text] [Related]  

  • 76. [Keep medical education independent! It should not be a scene of drug industry marketing].
    Eliasson G; Håkansson J
    Lakartidningen; 2001 Sep; 98(39):4168-9. PubMed ID: 11680148
    [No Abstract]   [Full Text] [Related]  

  • 77. 'One pill makes you larger...'. Don't be seduced by pharmaceutical companies.
    Mason DJ
    Am J Nurs; 2000 Dec; 100(12):7. PubMed ID: 11202788
    [No Abstract]   [Full Text] [Related]  

  • 78. Pfizer Night at Boston Billiards.
    Sharfstein J
    N Engl J Med; 1997 Jul; 337(2):134. PubMed ID: 9221345
    [No Abstract]   [Full Text] [Related]  

  • 79. Ties that bind? The web of CME and medical industry profit.
    Busby J
    Tex Med; 1991 Aug; 87(8):38-46. PubMed ID: 1925989
    [No Abstract]   [Full Text] [Related]  

  • 80. Drug rep advice raises gift ethics concerns.
    Greene J
    Minn Med; 2001 Jan; 84(1):22-3. PubMed ID: 11202522
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.